FDA, Penn make it personal
Executive Summary
FDA and the University of Pennsylvania sign a five-year memorandum of understanding aimed at advancing drug/device co-development, companion diagnostics, translational medicine and new clinical trial models, among other goals, FDA announces Sept. 9. The two hope to develop safer, more effective drugs, devices, and biologics targeted at individuals rather than broad populations, a growing focus for FDA and for industry. The agreement also facilitates exchanges between FDA personnel and Penn students and faculty, which could help FDA recruitment efforts